THE USE OF PROSTAGLANDIN E1 IN THE TREATMENT OF PURULENTINFLAMMATORY DISEASES
Abstract
The review article is devoted to current ideas about the advantages of using prostaglandin E1 drugs in the complex treatment of patients with various inflammatory and purulent-destructive diseases by the method of long-term intra-arterial perfusion. The study of the available literature on the benefits of intra-arterial access of drugs and the main therapeutic effects of prostaglandin-type drugs was carried out. The main areas of application of PGE1 in the treatment of patients with diseases associated with tissue ischemia have been identified.
The main mechanism of formation of acute kidney injury of any etiology is decrease of kidney blood supply. The subject of study in destructive forms of acute purulent pyelonephritis is the state of renal hemodynamics. In experimental and then in clinical studies, a wide range of mechanisms of PGE1 action have been shown, many of which underlie the therapeutic effect of prostaglandin-type drugs.
About the Authors
V. N. Pavlov
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
V. A. Vorobyov
ФГБОУ ВО «Иркутский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
V. A. Ananiev
КГБУЗ «Краевая клиническая больница»
Russian Federation
Russian Federation
References
1. Makarenko, T.A. Gnojnye vospalitel'nye zabolevanija pridatkov matki. Jetiologija, patogenez, klinika, principy differencirovannoj terapii (Purulent inflammatory diseases of the uterine appendages. Etiology, pathogenesis, clinic, principles of differentiated therapy): avtoref. diss. … d-ra med. nauk. Novosibirsk, 2013:4. (in Russ)
2. Balakshina N.G. Risk factors for purulent inflammatory diseases of the uterine appendages and aspects of surgical treatment. Siberian Medical Journal. [Tomsk]. 2009; 2: 112-117. (in Russ)
3. Zajcev, R.M. Obosnovanie vnutriaortal'noj terapii bol'nyh ostrym destruktivnym pankreatitom v posleoperacionnom periode (Substantiation of intra-aortic therapy in patients with acute destructive pancreatitis in the postoperative period): dis kand. med. nauk. Saransk, 2007:127. (in Russ)
4. Trubacheva A.V., Dolgikh V.T., Anishchenko V.V., Kuznetsov Yu.V. Methods of diagnosis and results of treatment of patients with pancreatic necrosis of moderate severity. Siberian Medical Journal (Irkutsk). 2014;124(1):34-38. (in Russ)
5. Yakovlev A.Y. [et al.] Pancreatoprotection with malate-containing infusion solutions in experimental hemorrhagic shock. Modern Medicine. technol. in medicine. 2013;5(2):25-29. (in Russ)
6. Pacher P., Beckman J., Liaudet Z. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev.2007; 87: 315–424. (in Engl)
7. Lubyansky V.G., Harutyunyan G.A. [et al.] Correction of regional blood circulation in the complex treatment of patients with acute pancreatitis. Ann. hir. hepatol. 2014; 3: 86-92. (in Russ)
8. Pokrovsky K.A.[et al.] The effectiveness of regional intraarterial therapy in the complex treatment of patients with pancreatic necrosis. Moscow. khir. zhurnal. 2009;5(9):38-41. (in Russ)
9. Garaev M.P., Nartalakov M.A., Loginov M.O. [et all.] Endovascularnaya terapiya v kompleksnom lechenii rasprostranennogo peritonita // Creativnaya chirurgiya and oncologiya.2024;14(1):36-41 (In Russ.)
10. Kazunori T. Antiproteases in the treatment of acute necrotizing pancreatitis: continuous regional arterial infusion. JOP. J. Pancreas (Online). 2007; 8(4):526–532. (in Engl)
11. Jahagirdar V. [et al.]. Prostaglandin E1 administration post liver transplantation and renal outcomes: a retrospective single center experience // World J. Transplant. 2024; 4 (14):98797. (in Engl)
12. Acciavatti A. [et al.]. Effects of alprostadil on blood rheology and nucleoside metabolism in patients affected with lower limb chronic ischaemia. Clin. Hemorheol. Microcirc. 2001; 1(24):49-57. (in Engl)
13. PubChem Alprostadil [Electronic resourse]. URL: https://pubchem.ncbi.nlm.nih.gov/compound/5280723 (date access: 25.02.2025). (in Engl)
14. Fantone J.C. [et al.]. Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil // J. Immunol. 1983;4 (130):1495-1497. (in Engl)
15. Fantone J.C. [et al.]. Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production // Am. J. Pathol. 1984;1(115):9-16. (in Engl)
16. Shin M. [et al.]. Effectiveness of intraportal prostaglandin E1 administration after liver transplantation. Transplant. Proc. 2012;2 (44):500–504. (in Engl)
17. Leslie S.W., Jain A., Iqbal O.A. Alprostadil. — Treasure Island (FL): StatPearls Publishing, 2025: 3. (in Engl)
18. Hirai M., Nakayama R. Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease. Br. J. Surg. 1986;1(73):20-23. (in Engl)
19. Alprostadil (Systemic, Local) Monograph for Professionals – Drugs. com [Electronic resourse]. URL: https://www.drugs.com/monograph/alprostadil-systemic-local.html (date access: 25.02.2025). (in Engl)
20. Sibbald W.J. [et al.]. The effects of prostaglandin E1 on lung injury complicating hyperdynamic sepsis in sheep. Am. Rev. Respir. Dis. 1989;3 (139):674–681. (in Engl)
21. Chen H. [et al.]. Singleand multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. Clin. Drug Investig. 2015;3(35):151-157. (in Engl)
22. Prostaglandins | DrugBank Online [Electronic resourse]. URL: https://go.drugbank.com/categories/DBCAT000353 (date access: 25.02.2025). (in Engl)
23. Huyghe E. [et al.]. Therapeutic management of erectile dysfunction: the AFU/SFMS guidelines. Fr. J. Urol. 2024;3(35):102842. (in Engl)
24. Zhang Y. [et al.]. A novel strategy to induce penile erection during penile doppler ultrasound: oral sildenafil administration plus alprostadil injection. Aging Male. 2024; 1 (27):2339352. (in Engl)
25. Jia Y. [et al.]. Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury. World J. Clin. Cases. 2021; 6 (9):1284-1292. (in Engl)
26. Ananyev V.A., Pavlov V.N., Pushkarev A.M., Lubyansky V.G.. Results of organ-preserving treatment of acute purulent pyelonephritis. Urologiia. 2024;6: 37-44. (in Russ)
27. Bharathan V.K. [et al.]. Perioperative prostaglandin E1 infusion in living donor liver transplantation: a double-blind, placebo-controlled randomized trial. Liver Transplant. 2016; 8 (22):1067-1074. (in Engl)
28. Lange E. Current surgery/drug combination treatment of diabetic gangrene of the foot. Infection. 1991;19 Suppl. 6:S351-354. (in Engl)
29. Manasia A.R. [et al.]. Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. J. Am. Coll. Surg. 1996; 4 (182):347-352. (in Engl)
30. Bulkin V.A. Intraarterial administration of drugs in the complex treatment of severe inflammatory diseases of the maxillofacial region. Kazan Medical Journal. 1980; 61( 4):48-49. (in Russ)
31. Antsypovich EA, Molchanov VF, Kadyshev IuG, Brusnitsyna MA. Selektivnoe vnutriarterial'noe primenenie malykh doz tienama i vazaprostana v lechenii gnoĭnykh zabolevaniĭ stopy u bol'nykh sakharnom diabete (Selective intra-arterial use of small doses of thienam and vasaprostanin the treatment of suppurative diseases of the foot in patients with diabetes mellitus). Vestn Khir Im I I Grek. 1998;157(1):76-7. (in Russ). PMID: 9611324.
32. Rjabov A.L. Regionarnaja vnutriarterial'naja perfuzija kak jelement kompleksnogo lechenija ognestrel'noj travmy nizhnih konechnostej, oslozhnjonnoj ranevoj infekciej (Regional intraarterial perfusion as an element of complex treatment of gunshot injury of the lower extremities complicated by wound infection): avtoref. dis kand. med. nauk. M., 2010: 3-25. (in Russ)
33. Makarenko T.A. Results of organ—preserving treatment of purulent inflammatory diseases of the uterine appendages in women of reproductive age. Endoscope. khir. 2012; 2:38-41. (in Russ)
34. Arutjunjan G.A. Lokal'naja reologicheskaja terapija v kompleksnom lechenii bol'nyh s ostrym pankreatitom (Local rheological therapy in the complex treatment of patients with acute pancreatitis): avtoreferat dis. … kand. med. nauk. Barnaul, 2018:23. (in Russ)
35. Sposob lechenija rasprostranjonnyh gnojnyh peritonitov putjom selektivnoj vnutrisosudistoj infuzii v verhnjuju bryzheechnuju arteriju i vakuum-assistirovannoj laparostomii (A method for the treatment of common purulent peritonitis by selective intravascular infusion into the superior mesenteric artery and vacuum-assisted laparostomy): pat. 2785496 C1 Ros. Federacija; zajavl. 15.03.2022; opubl. 8.12.2022. Bjul. № 34:11. (in Russ)
36. Fu H, Hou W, Zhang Y, Hu X. Alprostadil for hypertensive nephropathy: a systematic review and meta-analysis of randomized controlled trials // PLoS One. – 2022. – № 17(5):e0269111. DOI:10.1371/journal.pone.0269111
37. Alhewy MA, Abdo EM, Ghazala EA, [et al.]. Outcomes of alprostadil as an adjuvant therapy with indirect angiosomal revascularization in patients with critical limb ischemia after failure of direct revascularization // Ann Vasc Surg. – 2024. – 103:58–67. DOI:10.1016/j.avsg.2023.12.078.
38. Nayak AP, Javed E, Villalba DR, [et al.]. Prorelaxant E type prostanoid receptors functionally partition to different procontractile receptors in airway smooth muscle // Am J Respir Cell Mol Biol. – 2023. – № 69(5):584–591. DOI:10.1165/rcmb.2022-0445OC.
39. Somkereki C, Palfi R, Scridon A. Prevention of contrast associated acute kidney injury in an era of increasingly complex interventional procedures // Front Med (Lausanne). – 2024. – 10:1180861. DOI:10.3389/fmed.2023.1180861.
40. Gordon CM, Tan JT, Carr RR. Effectiveness of alprostadil for ductal patency // J Pediatr Pharmacol Ther. – 2024. – № 29(1):37–44. DOI:10.5863/1551-6776-29.1.37.
41. Li X, Wang Y, Liu S, [et al.]. Roles of EP receptors in the regulation of fluid balance and blood pressure // Front Endocrinol (Lausanne). – 2022. – 13:875425. DOI:10.3389/fendo.2022.875425.
Review
For citations:
Pavlov V.N., Vorobyov V.A., Ananiev V.A. THE USE OF PROSTAGLANDIN E1 IN THE TREATMENT OF PURULENTINFLAMMATORY DISEASES. Bashkortostan Medical Journal. 2025;20(3):94-101. (In Russ.)
Views:
15
Email this article 
